How Gstt2 Affects Bladder Cancer Treatment with BCG
Author Information
Author(s): Patwardhan Mugdha V., Kane Toh Qin, Chiong Edmund, Rahmat Juwita Norasmara, Mahendran Ratha
Primary Institution: National University of Singapore
Hypothesis
Gstt2 deletion results in cellular and molecular alterations in the tumor microenvironment, resulting in beneficial BCG responses.
Conclusion
Patients with wildtype Gstt2 may benefit from anti-PD-L1 checkpoint inhibition therapy.
Supporting Evidence
- Loss of Gstt2 expression is associated with an improved response to BCG immunotherapy.
- BCG treatment led to a more pronounced decline in urinary PSA levels in Gstt2 KO mice.
- An 11-gene signature predicted response in NMIBC patients.
Takeaway
This study found that a gene called Gstt2 can change how bladder cancer responds to a treatment called BCG, which helps the immune system fight cancer.
Methodology
Gstt2 WT and KO C57BL/6J mice were implanted with tumors and treated with BCG or saline, followed by RNA analysis via single-cell RNA sequencing and real-time PCR.
Limitations
The study's findings may be limited by the variability in tumor sizes and the use of whole bladders for gene expression analysis.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website